(NASDAQ: ASRT) Assertio Holdings's forecast annual revenue growth rate of -5.65% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 2.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 118.23%.
Assertio Holdings's revenue in 2025 is $117,097,000.On average, 1 Wall Street analysts forecast ASRT's revenue for 2025 to be $10,632,553,770, with the lowest ASRT revenue forecast at $10,632,553,770, and the highest ASRT revenue forecast at $10,632,553,770.
In 2026, ASRT is forecast to generate $11,065,632,083 in revenue, with the lowest revenue forecast at $11,065,632,083 and the highest revenue forecast at $11,065,632,083.